Company Overview and News
2018-10-12 seekingalpha - 5
This article first appeared on Trend Investing on Aug. 14, 2018; therefore all data is as of that date.
MOMO NFLX HPE VZA SWKS AAPL CSCO NOK INTC CSCOI CHLKF VOD VOD HXSCF BC94 SMSN 0941 S CHL VODPF GOOGL MU VZ MSFT QCOM HXSCL SMSD
2018-10-09 investorplace - 1
Telecommunications technology has always been an ultra-competitive business. But with the advent of airwave auctions, figuring out which 5G stocks to buy just got a lot more interesting. Sector players are leaving no stone unturned as they battle for prime network coverage. Municipalities and entire nations selling their airwave rights in return for lucrative contracts with telecom giants is nothing new.
SWKS T VOD AMT TWX AAPL VZ QCOM INTC TWC
2018-10-08 247wallst - 1
Stocks were looking to open lower on Monday, but it was expected to be a fairly quiet day with the Columbus Day holiday keeping part of the banking system closed. U.S. equity indexes are just under all-time highs, but investors have been seeing lower upside from buying on market pullbacks than in prior years. Now the investing community has to consider how they want to position their investments for the rest of 2018 and into 2019.
HAL FB ABT WMT HUN AAPL CAG TMHC ABT SLB EA GE GEC VOD VOD CBT BHGE KMB PBR MDT BHI BLK VODPF TRI GNE SCL SLB
2018-10-03 sec.gov - 1
U.S. stocks rose on Wednesday, with the Dow Jones Industrial Average hitting its latest in a series of records and aiming for a fifth straight positive session.
FB VOD ADPVV VOD VODPF ADP TPX DTK RPM
2018-10-03 bworldonline - 1
THE UK’s Vodafone Group PLC has discussed with the government the possibility of participating in the selection process for the telecommunications industry’s so-called “third player,” Budget Secretary Benjamin E. Diokno said following a visit to London.
K3ED VOD CHJHF VOD VODPF NOW KT CHA 0728 ECP DNOW
October 2, 2018: Here are four stocks trading with heavy volume among 173 equities making new 52-week lows in Tuesday’s session. On the NYSE decliners led advancers by about 1.83 to 1, and on the Nasdaq, decliners led advancers by about 2.08 to 1.
VOD VOD VODPF RAD LYG SNAP
SINGAPORE (Oct 2): Axiata Group Bhd’s dream of building a carrier that spans southern Asia from Singapore to Pakistan, Indonesia and India is fading as it risks losing hold of overseas units to rivals.
SGPRY VOD VOD VODPF 6888 SGPRF IDEA ICLQY AXXTF 532822
2018-10-01 sec.gov - 1
2018-09-28 seekingalpha - 1
47 of 53 NASDAQ-100 Index dividends were presumed "safer" because they showed positive one-year returns and free cash flow yields greater than dividend yields as of 9/25/18.
LRCX VOD VOD GILD CMCSA WDC STX MCHP KLAC SWKS PEP VODPF AVGO QCOM INTC MXIM PAYX
SUNNYVALE, Calif., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Juniper Networks (NYSE: JNPR), an industry leader in automated, scalable and secure networks, today announced that Vodafone has selected the company as one of its Software-Defined Wide Area Network (SD-WAN) vendors for its enterprise-focused SDN portfolio, referred to as ‘Ready Network.’ Vodafone’s portfolio will comprise flexible, cloud-based services that are designed to underpin digital business at scale, helping enterprises to compete effectively using agile, open and fast infrastructure with zero-touch deployment.
VOD VOD VODPF JNPR
From 8/15/18-9/17/18, Fredrik Arnold dividend "followers" commented on 40 equities and funds. Some comments were bad news, so some rogues mixed in to create a FollowerFavorite/Rogue (FoFa/Ro) list.
KWH.UN VOD VOD SXCP CRIUF ORC DVDDF CHMI CZZ CJREF CIM GMLP VODPF CJR.B CVX AVGO BRCM INTC SNMP
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to VOD / Vodafone Group Plc on message board site Silicon Investor.
as of ET